Skip to content

Supernus Pharmaceuticals

US · SUPN #2636 by market cap Listed 1970
28.61 +0.26 +0.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:48

Quant vs Street three independent views, side by side

StockVane factor grade
D+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 6 analysts

Buy
Avg price target 52.60 +83.9%
Price target rangecurrent 28.61
Low37.00
Avg52.60
High87.00
Buy 83% Hold 17% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-09 BofA Securities -- Buy 47.00
2026-11-04 Piper Sandler -- Buy 47.00
2026-11-04 Stifel -- Hold 37.00
2026-11-03 Cantor Fitzgerald -- Buy 87.00
2026-10-30 BofA Securities -- Buy --
2026-10-30 Stifel -- Hold 55.00
2026-10-28 Barclays -- Buy 45.00
2026-10-21 TD Cowen -- Buy 65.00
2026-10-15 BofA Securities -- Buy 55.00
2026-10-12 BofA Securities -- Buy 60.00
2026-09-17 Craig-Hallum -- Buy --
2026-08-03 TD Cowen -- Buy 65.00
2026-07-27 Piper Sandler -- Buy 66.00
2026-07-13 BofA Securities -- Buy 63.00
2026-07-09 Cantor Fitzgerald -- Buy 67.00
2026-06-04 Piper Sandler -- Buy 66.00
2026-05-06 Piper Sandler -- Buy 66.00
2026-05-06 Stifel -- Hold 55.00
2026-05-05 TD Cowen -- Buy 65.00
2026-04-27 Piper Sandler -- Buy 66.00
2026-04-23 TD Cowen -- Buy 65.00
2026-04-13 Piper Sandler -- Buy 66.00
2026-02-25 TD Cowen -- Buy 65.00
2026-02-25 Stifel -- Hold 55.00
2026-02-24 TD Cowen -- Buy 65.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-10-29 After close ±12.09% +0.34% (in line)
2026/Q2 2026-08-04 After close ±11.59% +6.11% (in line)
2026/Q1 2026-05-05 After close ±12.36% +2.58% (in line)
2025/Q4 2026-02-24 After close ±13.52% +1.72% (in line)
2025/Q3 2025-11-04 After close ±11.23% +0.16% (in line)
2025/Q2 2025-08-05 After close -- +0.92%
2025/Q1 2025-05-06 After close ±12.30% -1.88% (in line)
2024/Q4 2025-02-25 After close ±8.52% +3.87% (in line)
2024/Q3 2024-11-04 After close ±10.88% +0.33% (in line)
2024/Q2 2024-08-06 After close ±10.67% -2.22% (in line)
2024/Q1 2024-05-08 After close ±11.47% +0.51% (in line)
2023/Q4 2024-02-27 After close ±20.19% -1.57% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.

Supernus Pharmaceuticals discussion 0 comments

Add a comment